Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Gene Therapy in a Patient with Sickle Cell Disease
source: The New England Journal of Medicine
year: 2017
authors: Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Caccavelli L, Neven B, Bourget P, El Nemer W, Bartolucci P, Weber L, Puy H, Meritet JF, Grevent D, Beuzard Y, Chrétien S, Lefebvre T, Ross RW, Negre O1, Veres G, Sandler L, Soni S, de Montalembert M, Blanche S, Leboulch P, Cavazzana M
summary/abstract:Sickle cell disease results from a homozygous missense mutation in the β-globin gene that causes polymerization of hemoglobin S. Gene therapy for patients with this disorder is complicated by the complex cellular abnormalities and challenges in achieving effective, persistent inhibition of polymerization of hemoglobin S. We describe our first patient treated with lentiviral vector-mediated addition of an antisickling β-globin gene into autologous hematopoietic stem cells. Adverse events were consistent with busulfan conditioning. Fifteen months after treatment, the level of therapeutic antisickling β-globin remained high (approximately 50% of β-like-globin chains) without recurrence of sickle crises and with correction of the biologic hallmarks of the disease.
DOI: 10.1056/NEJMoa1609677read more full text
Related Content
-
Sickle Cell Disease Association of America Michigan Chapter, Inc.The vision of Sickle Cell Disease Associ...
-
Chronic opioid therapy is more strongly associated with central sensitization in sickle cell disease than clinical p...Central nervous system sensitization (CS...
-
Edward Donnell IvyEdward Donnell Ivy is a Director of Outr...
-
Hatoon Ezzat, MBBS, FRCPC, ABIMDr. Hatoon Ezzat received her medical de...
-
Coronavirus Questions: Getting Answers From the Expertshttps://www.youtube.com/watch?v=iFavuPKV...
-
Stress and the Home Environment in Caregivers of Children With Sickle CellObjective: Caregivers of young children...
-
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.